Interventional, Randomized, Double-blind, Active-controlled Study of the Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2018
At a glance
- Drugs LU AF-35700 (Primary) ; Olanzapine; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms Anew
- Sponsors Lundbeck A/S
- 12 Oct 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Sep 2020.
- 04 Oct 2018 Phase has changed from phase 2 to phase 3, hence the protocol was amended.
- 04 Oct 2018 Planned number of patients changed from 285 to 817.